Ronald Maceyko, MD
Dermatology · Pittsburgh, PANPI 1417030560
Payments from drug & device makers
Across 22 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$161
- AbbVie$72
- Pfizer$70
- Dermavant Sciences, Inc.$49
- Lilly USA, LLC$41
- Novartis$40
- plus $155 from 6 others
What the payments were for
- Food & beverage$55995%
- Education$285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 3 | $161 |
| AbbVie | 1 | $72 |
| Pfizer | 4 | $70 |
| Dermavant Sciences, Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $41 |
| Novartis | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Sanofi | 1 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Merz North America, Inc. | 1 | $13 |
How this compares
$587 in reported general payments places this provider in the 30th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 20 | $95,973 |
| Dupixent SyringeDupilumab | 25 | $87,444 |
| Dupixent PenDupilumab | 12 | $45,860 |
| Metronidazole | 68 | $4,032 |
| Calcipotriene | 22 | $3,671 |
| Ketoconazole | 112 | $2,338 |
| Clobetasol Propionate | 65 | $2,298 |
| Tacrolimus | 28 | $2,101 |
| Fluocinonide | 47 | $1,590 |
| Tretinoin | 15 | $1,127 |
| Fluorouracil | 14 | $1,115 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $910 |
| Clindamycin Phosphate | 19 | $865 |
| Triamcinolone Acetonide | 57 | $524 |
| Dexamethasone | 11 | $395 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Pittsburgh
- Laura FerrisPittsburgh$4.3M
- Joe TungPittsburgh$1.5M
- Oleg AkilovPittsburgh$1.3M
- Neil NirenPittsburgh$574K
- Timothy PattonPittsburgh$276K
- Charles MountPittsburgh$189K
- Daniel KaplanPittsburgh$165K
- Hassane ZarourPittsburgh$131K
- Victoria WerthPhiladelphia$7.2M
- Joel GelfandPhiladelphia$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.